STAINES-UPON-THAMES, United
Kingdom, July 9, 2020
/PRNewswire/ -- Mallinckrodt
plc (NYSE: MNK), a global biopharmaceutical company, announced
today that it will report second quarter 2020 earnings results for
the period ended June 26, 2020 on Tuesday, Aug. 4, 2020.
A conference call for investors will begin at 8:30
a.m. Eastern Time. The call can be accessed in three ways:
- At
the Mallinckrodt website: http://mallinckrodt.com/investors/events-calendar/.
- By telephone: For both listen-only participants and those who
wish to take part in the question-and-answer portion of the call,
the telephone dial-in number in the U.S. is (877) 359-9508. For
participants outside the U.S., the dial-in number is (224)
357-2393. Callers will need to provide the Conference ID of
5970869. Dial-in 15 minutes in advance of the call is encouraged to
avoid connection delays.
- Through an audio replay: A replay of the call will be available
beginning at 11:30 a.m. Eastern Time on Tuesday,
Aug. 4, 2020, and ending at 11:30 a.m. Eastern Time
on Tuesday, Aug. 18, 2020. Dial-in numbers for U.S.-based
participants are (855) 859-2056 or (800) 585-8367. Participants
outside the U.S. should use the replay dial-in number of (404)
537-3406. All callers will be required to provide the Conference ID
of 5970869.
ABOUT MALLINCKRODT
Mallinckrodt is a global business consisting of
multiple wholly owned subsidiaries that develop, manufacture,
market and distribute specialty pharmaceutical products and
therapies. The company's Specialty Brands reportable segment's
areas of focus include autoimmune and rare diseases in specialty
areas like neurology, rheumatology, nephrology, pulmonology and
ophthalmology; immunotherapy and neonatal respiratory critical care
therapies; analgesics and gastrointestinal products. Its Specialty
Generics reportable segment includes specialty generic drugs and
active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.
Mallinckrodt uses its website as a
channel of distribution of important company information, such as
press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission (SEC) disclosing the same
information. Therefore, investors should look to the Investor
Relations page of the website for important and time-critical
information. Visitors to the website can also register to receive
automatic e-mail and other notifications alerting them when new
information is made available on the Investor Relations page of the
website.
CONTACTS
Investor Relations
Daniel J. Speciale, CPA
Vice President, Finance and Investor Relations Officer
(314) 654-3638
daniel.speciale@mnk.com
Financial/Dailies Media Inquiries
Ron Bartlett
H+K Strategies
Senior Vice President
813-545-2399
ron.bartlett@hkstrategies.com
Mallinckrodt, the "M" brand mark and
the Mallinckrodt Pharmaceuticals logo are trademarks of a
Mallinckrodt company. Other brands are
trademarks of a Mallinckrodt company or
their respective owners. © 2020
Mallinckrodt. 07/2020
View original content to download
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-to-report-earnings-results-for-second-quarter-2020-301090457.html
SOURCE Mallinckrodt Pharmaceuticals